PMC:7510993 / 6778-8587 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T3","span":{"begin":1626,"end":1630},"obj":"Body_part"},{"id":"T4","span":{"begin":1675,"end":1679},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma12520"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma12520"}],"text":"Regarding region-specific host susceptibility to COVID-19, we collected data on the following three epidemiologic properties: the proportion of the population aged over 65 years, the malaria incidence (per year), and information regarding bacillus Calmette–Guérin (BCG) vaccination. We included these attributes in our analyses based on the assumptions that BCG vaccination and/or recurrent treatment with anti-malarial medications could be associated with providing some protection against COVID-19 [13, 14]. We compiled BCG data from the WHO (https://www.who.int/malaria/data/en/) and (https://apps.who.int/gho/data/view.main.80500?lang=en) and the BCG Atlas Team (http://www.bcgatlas.org/) on the following five attributes: i) the number of years since BCG vaccination was started (BCG_year); ii) the present situation regarding BCG vaccination (BCG_type), split into all vaccinated, partly vaccinated, vaccinated once in the past, or never vaccinated; iii) the relative frequency of post-1980 (i.e., the past 40 years) BCG vaccination for people aged less than 1 year old (BCG_rate); iv) the number of BCG vaccinations (MultipleBCG), describing countries as never having vaccinated their citizens with BCG, vaccinated their citizens with BCG only once, vaccinated their citizens with BCG multiple times in the past, or currently vaccinate their citizens with BCG multiple times; and v) tuberculosis cases per 1 million people (TB). These BCG-related variables are strongly intercorrelated. Therefore, we reduced the dimensions of these variables (BCG_year, BCG_type, BCG_rate, MultipleBCG, and TB) by extracting the first axis of the PCA analysis: the score of the PCA 1 axis was negatively correlated with the five variables, so the PCA 1 score multiplied by –1 was defined as the BCG vaccination effect."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T50","span":{"begin":49,"end":57},"obj":"Disease"},{"id":"T51","span":{"begin":183,"end":190},"obj":"Disease"},{"id":"T52","span":{"begin":491,"end":499},"obj":"Disease"},{"id":"T53","span":{"begin":565,"end":572},"obj":"Disease"},{"id":"T54","span":{"begin":1390,"end":1402},"obj":"Disease"},{"id":"T55","span":{"begin":1431,"end":1433},"obj":"Disease"},{"id":"T56","span":{"begin":1598,"end":1600},"obj":"Disease"}],"attributes":[{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0005136"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0005136"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"}],"text":"Regarding region-specific host susceptibility to COVID-19, we collected data on the following three epidemiologic properties: the proportion of the population aged over 65 years, the malaria incidence (per year), and information regarding bacillus Calmette–Guérin (BCG) vaccination. We included these attributes in our analyses based on the assumptions that BCG vaccination and/or recurrent treatment with anti-malarial medications could be associated with providing some protection against COVID-19 [13, 14]. We compiled BCG data from the WHO (https://www.who.int/malaria/data/en/) and (https://apps.who.int/gho/data/view.main.80500?lang=en) and the BCG Atlas Team (http://www.bcgatlas.org/) on the following five attributes: i) the number of years since BCG vaccination was started (BCG_year); ii) the present situation regarding BCG vaccination (BCG_type), split into all vaccinated, partly vaccinated, vaccinated once in the past, or never vaccinated; iii) the relative frequency of post-1980 (i.e., the past 40 years) BCG vaccination for people aged less than 1 year old (BCG_rate); iv) the number of BCG vaccinations (MultipleBCG), describing countries as never having vaccinated their citizens with BCG, vaccinated their citizens with BCG only once, vaccinated their citizens with BCG multiple times in the past, or currently vaccinate their citizens with BCG multiple times; and v) tuberculosis cases per 1 million people (TB). These BCG-related variables are strongly intercorrelated. Therefore, we reduced the dimensions of these variables (BCG_year, BCG_type, BCG_rate, MultipleBCG, and TB) by extracting the first axis of the PCA analysis: the score of the PCA 1 axis was negatively correlated with the five variables, so the PCA 1 score multiplied by –1 was defined as the BCG vaccination effect."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T31","span":{"begin":578,"end":580},"obj":"http://purl.obolibrary.org/obo/CLO_0037161"},{"id":"T32","span":{"begin":639,"end":641},"obj":"http://purl.obolibrary.org/obo/CLO_0037161"}],"text":"Regarding region-specific host susceptibility to COVID-19, we collected data on the following three epidemiologic properties: the proportion of the population aged over 65 years, the malaria incidence (per year), and information regarding bacillus Calmette–Guérin (BCG) vaccination. We included these attributes in our analyses based on the assumptions that BCG vaccination and/or recurrent treatment with anti-malarial medications could be associated with providing some protection against COVID-19 [13, 14]. We compiled BCG data from the WHO (https://www.who.int/malaria/data/en/) and (https://apps.who.int/gho/data/view.main.80500?lang=en) and the BCG Atlas Team (http://www.bcgatlas.org/) on the following five attributes: i) the number of years since BCG vaccination was started (BCG_year); ii) the present situation regarding BCG vaccination (BCG_type), split into all vaccinated, partly vaccinated, vaccinated once in the past, or never vaccinated; iii) the relative frequency of post-1980 (i.e., the past 40 years) BCG vaccination for people aged less than 1 year old (BCG_rate); iv) the number of BCG vaccinations (MultipleBCG), describing countries as never having vaccinated their citizens with BCG, vaccinated their citizens with BCG only once, vaccinated their citizens with BCG multiple times in the past, or currently vaccinate their citizens with BCG multiple times; and v) tuberculosis cases per 1 million people (TB). These BCG-related variables are strongly intercorrelated. Therefore, we reduced the dimensions of these variables (BCG_year, BCG_type, BCG_rate, MultipleBCG, and TB) by extracting the first axis of the PCA analysis: the score of the PCA 1 axis was negatively correlated with the five variables, so the PCA 1 score multiplied by –1 was defined as the BCG vaccination effect."}

LitCovid-PD-CHEBI

LitCovid-PubTator

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T37","span":{"begin":0,"end":282},"obj":"Sentence"},{"id":"T38","span":{"begin":283,"end":509},"obj":"Sentence"},{"id":"T39","span":{"begin":510,"end":1435},"obj":"Sentence"},{"id":"T40","span":{"begin":1436,"end":1493},"obj":"Sentence"},{"id":"T41","span":{"begin":1494,"end":1809},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Regarding region-specific host susceptibility to COVID-19, we collected data on the following three epidemiologic properties: the proportion of the population aged over 65 years, the malaria incidence (per year), and information regarding bacillus Calmette–Guérin (BCG) vaccination. We included these attributes in our analyses based on the assumptions that BCG vaccination and/or recurrent treatment with anti-malarial medications could be associated with providing some protection against COVID-19 [13, 14]. We compiled BCG data from the WHO (https://www.who.int/malaria/data/en/) and (https://apps.who.int/gho/data/view.main.80500?lang=en) and the BCG Atlas Team (http://www.bcgatlas.org/) on the following five attributes: i) the number of years since BCG vaccination was started (BCG_year); ii) the present situation regarding BCG vaccination (BCG_type), split into all vaccinated, partly vaccinated, vaccinated once in the past, or never vaccinated; iii) the relative frequency of post-1980 (i.e., the past 40 years) BCG vaccination for people aged less than 1 year old (BCG_rate); iv) the number of BCG vaccinations (MultipleBCG), describing countries as never having vaccinated their citizens with BCG, vaccinated their citizens with BCG only once, vaccinated their citizens with BCG multiple times in the past, or currently vaccinate their citizens with BCG multiple times; and v) tuberculosis cases per 1 million people (TB). These BCG-related variables are strongly intercorrelated. Therefore, we reduced the dimensions of these variables (BCG_year, BCG_type, BCG_rate, MultipleBCG, and TB) by extracting the first axis of the PCA analysis: the score of the PCA 1 axis was negatively correlated with the five variables, so the PCA 1 score multiplied by –1 was defined as the BCG vaccination effect."}